January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
34 citations
,
July 1993 in “PubMed” February 2023 in “Sexual Medicine Reviews” April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
December 2016 in “The journal of sexual medicine” Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.
92 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
11 citations
,
April 2018 in “Journal of Dermatology” Dutasteride safely treats hair loss without harming sexual function.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
January 2024 in “Saudi pharmaceutical journal” The study successfully formulated and optimized a bilayer tablet combining Tamsulosin and Finasteride using response surface methodology.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
1 citations
,
April 1999 in “The Journal of Urology” 14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism”
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
May 2024 in “News Digital Object Group” 9 citations
,
April 2013 in “Journal of Chromatography B” A reliable method was created to measure tamsulosin in human blood.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
Titanflow improves male urinary health by strengthening the detrusor muscle and enhancing urine flow.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
1 citations
,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
Testosterone undecanoate can reduce the negative effects of Finasteride on male reproductive health.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.